Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Movement Disorders

• Publication date

  2014-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/mds.25778PMID 24357540
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The common PARK8 mutation LRRK2G2019S is not a risk factor for breast cancer in the absence of Parkinson’s disease

  2013cited by this paper
• The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers

  2012cited by this paper
• PINK1 displays tissue-specific subcellular location and regulates apoptosis and cell growth in breast cancer cells.

  2011cited by this paper
• LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease

  2010cited by this paper
• Parkinson’s disease and cancer risk: a systematic review and meta-analysis

  2010cited by this paper
• FAMILY HISTORY OF MELANOMA AND PARKINSON DISEASE RISK

  2010cited by this paper
• Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain)

  2010cited by this paper
• Comorbid cancer in Parkinson's disease

  2010cited by this paper
• Parkinson's disease and cancer: the unexplored connection.

  2010cited by this paper
• Common pathogenic pathways in melanoma and Parkinson disease

  2010cited by this paper
• Cancer risk in association with Parkinson disease: a population-based study.

  2010cited by this paper
• LRRK2 G2019S and R1441G mutations associated with Parkinson’s disease are common in the Basque Country, but relative prevalence is determined by ethnicity

  2009cited by this paper
• Family history of melanoma and Parkinson disease risk

  2009cited by this paper
• The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation

  2009cited by this paper
• ARE PARKINSON DISEASE PATIENTS PROTECTED FROM SOME BUT NOT ALL CANCERS?

  2008cited by this paper
• Patterns of somatic mutation in human cancer genomes

  2007cited by this paper
• A Prospective Cohort Study of Cancer Incidence Following the Diagnosis of Parkinson's Disease

  2007cited by this paper
• Are Parkinson disease patients protected from some but not all cancers?

  2007cited by this paper
• Tumours and tremors: how PTEN regulation underlies both

  2006cited by this paper
• Kinase activity of mutant LRRK2 mediates neuronal toxicity

  2006cited by this paper
• Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature

  2006cited by this paper
• Malignant Melanoma and Other Types of Cancer Preceding Parkinson Disease

  2006cited by this paper
• Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.

  2005cited by this paper
• LRRK2 mutations and Parkinsonism.

  2005cited by this paper
• LRRK2 mutations and Parkinsonism.

  2005cited by this paper
• Risk of cancer after the diagnosis of Parkinson's disease: A historical cohort study

  2005cited by this paper
• Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

  2004cited by this paper
• Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?

  2003cited by this paper
• Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25–q27

  2003cited by this paper
• Mortality and cancer incidence in patients with Parkinson's disease

  2000cited by this paper
• Diagnostic criteria for Parkinson disease.

  1999cited by this paper
• Occurrence of different cancers in patients with Parkinson's disease

  1995cited by this paper

• HTT, ATXN1 and ATXN2 CAG triplet repeat sizes: exploring their role in the disease risk and cancer comorbidity in Parkinson’s disease

  2025cites this paper
• Ubiquitin-specific protease 7 promotes the growth and oncogenic potential of acute myeloid leukemia cells through the deubiquitination and upregulation of LRRK2

  2025cites this paper
• Association of Sporadic and Genetic Parkinson’s Disease with Cancer: Insights from the PPMI Cohort

  2025cites this paper
• Suppression of Glioblastoma Stem Cell Potency and Tumor Growth via LRRK2 Inhibition

  2024cites this paper
• Double Trouble: Association of Malignant Melanoma with Sporadic and Genetic Forms of Parkinson’s Disease and Asymptomatic Carriers of Related Genes: A Brief Report

  2023cites this paper
• Leucine-rich repeat kinase 2 at a glance

  2023cites this paper
• Parkinson’s disease and cancer: a systematic review and meta-analysis on the influence of lifestyle habits, genetic variants, and gender

  2022influential citation
• In silico comparative analysis of LRRK2 interactomes from brain, kidney and lung

  2021cites this paper
• Cancer in Parkinson’s Disease, a Review of Literature

  2021cites this paper
• Leucine rich repeat kinase 2 (LRRK2) peptide modulators: Recent advances and future directions

  2021cites this paper
• Parkinson’s disease and cancer: a systematic review and meta-analysis of over 17 million participants

  2021cites this paper
• The development of inhibitors of leucine‐rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play

  2021cites this paper
• Loss of Parkinson’s susceptibility gene LRRK2 promotes carcinogen-induced lung tumorigenesis

  2021cites this paper
• Comprehensive Genomic Analysis Reveals the Prognostic Role of LRRK2 Copy-Number Variations in Human Malignancies

  2020cites this paper
• The Links between Parkinson’s Disease and Cancer

  2020cites this paper
• Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls

  2019cites this paper
• LRRK2 is involved in the pathogenesis of system lupus erythematosus through promoting pathogenic antibody production

  2019cites this paper
• LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same

  2019cites this paper
• Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease

  2017cites this paper
• Clinical Features of LRRK2 Carriers with Parkinson's Disease.

  2017cites this paper
• Biological and Clinical Implications of Comorbidities in Parkinson’s Disease

  2017cites this paper
• Does Parkinson ’ s Disease Dementia Reduce Cancer Risk more than Alzheimer ’ s Disease Alone ?

  2017cites this paper
• Computational analysis of the LRRK2 interactome

  2015influential citation
• Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

  2015cites this paper
• Transgenic LRRK2R1441G rats–a model for Parkinson disease?

  2015cites this paper
• The associations between Parkinson’s disease and cancer: the plot thickens

  2015cites this paper
• Investigating the Multiple Hit hypothesis of Parkinson disease using transgenic LRRK2-R1441G rats

  2014cites this paper
• LRRK2‐G2019S mutation is not associated with an increased cancer risk: A kin‐cohort study

  2014cites this paper
• Chapter 2 Clinical Features of LRRK 2 Carriers with Parkinson ’ s Disease

  year unknowncites this paper